PLK1 and lung adenocarcinoma: Similar to the above results, PLK1 promoter methylation levels were lower in thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), lung adenocarcinoma (LUAD), rectum adenocarcinoma (READ), bladder urothelial carcinoma (BLCA), liver hepatocellular carcinoma (LIHC), esophageal carcinoma (ESCA) and testicular germ cell tumors (TGCT) compared to the normal tissues (Supplementary Figure 13).